Browsing by Subject "clinical studies"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Rationale and Design of a Prospective, Multicenter, Observational Study Evaluating Iron Deficiency in Patients Hospitalized for Heart Failure (FERIC-RO)
    (Universidad Nacional de Trujillo, 2018-07-01) Antohi, Elena Laura; Chitoiu, Gabriel Tatu; Ambrosy, Andrew P.; Coman, Ioan M.; Vinereanu, Dragos; Collins, Sean P.; Sinescu, Crina; Mihaileanu, Serban; Pang, Peter S.; Butler, Javed; Chioncel, Ovidiu; Emergency Medicine, School of Medicine
    Introduction: Several landmark studies, which enrolled heart failure (HF) patients who were ambulatory at the time of inclusion, identified iron deficiency (ID) as an important therapeutic target: intravenous iron administration with ferric carboxymaltose (FCM) improves morbidity, exercise capacity, and quality of life in patients with HF and reduced EF (HFrEF). However, there is still limited knowledge about ID prevalence during hospitalization for Worsening Chronic HF (WCHF) and about the relationship between ID during hospitalization and post-discharge outcomes. Although previous studies documented ID as an independent risk factor for poor outcomes in HFrEF, its prognostic significance in HF patients with EF>40% remains unclear. Method and Results: The FERIC-RO study is a prospective, multicenter, observational study with longitudinal follow up, conducted in 9 Romanian hospitals that will include 200 consecutive patients admitted for worsening HF. A comprehensive description of the Iron metabolism biomarkers will be performed on discharge and 1-month follow up. The primary endpoint is defined as the prevalence of ID on discharge and 1-month post-discharge, and the secondary endpoints include: all-cause re-hospitalization and all-cause-mortality at 1 and 3 months follow up, and quality of life on discharge and 1-month. Conclusions: FERIC-RO will provide new evidence about the prevalence and the predictors of ID in patients hospitalized for WCHF regardless of LVEF. Furthermore, the study will explore the relationship between in-hospital ID and post-discharge outcomes. The results of FERIC-RO will thus be highly relevant to the management of patients hospitalized for AHF.
  • Thumbnail Image
    Item
    Sources, Production, and Clinical Treatments of Milk Fat Globule Membrane for Infant Nutrition and Well-Being
    (MDPI, 2020-05-30) Fontecha, Javier; Brink, Lauren; Wu, Steven; Pouliot, Yves; Visioli, Francesco; Jiménez-Flores, Rafael; Pediatrics, School of Medicine
    Research on milk fat globule membrane (MFGM) is gaining traction. The interest is two-fold; on the one hand, it is a unique trilayer structure with specific secretory function. On the other hand, it is the basis for ingredients with the presence of phospho- and sphingolipids and glycoproteins, which are being used as food ingredients with valuable functionality, in particular, for use as a supplement in infant nutrition. This last application is at the center of this Review, which aims to contribute to understanding MFGM’s function in the proper development of immunity, cognition, and intestinal trophism, in addition to other potential effects such as prevention of diseases including cardiovascular disease, impaired bone turnover and inflammation, skin conditions, and infections as well as age-associated cognitive decline and muscle loss. The phospholipid composition of MFGM from bovine milk is quite like human milk and, although there are some differences due to dairy processing, these do not result in a chemical change. The MFGM ingredients, as used to improve the formulation in different clinical studies, have indeed increased the presence of phospholipids, sphingolipids, glycolipids, and glycoproteins with the resulting benefits of different outcomes (especially immune and cognitive outcomes) with no reported adverse effects. Nevertheless, the precise mechanism(s) of action of MFGM remain to be elucidated and further basic investigation is warranted.
  • Thumbnail Image
    Item
    Using Structural Docking for Drug Repurposing
    (Office of the Vice Chancellor for Research, 2011-04-08) Sanders, Philip
    Recently the FDA has increased restrictions making it very difficult to get a new drug out. Therefore it is desirable to repurpose a drug already in use, one which has passed clinical studies and has few side effects. For this reason we created a method to repurpose existing drugs to treat diseases other than their known targets. In this study we chose to demonstrate our method on colorectal cancer. CRC is an interesting disease for this approach, as known CRC chemotherapy drugs are ineffective in curing this kind of cancer. To find repurposed drugs for CRC we first use a structural algorithm to identify probable CRC gene targets for a specific set of in market cancer drugs. After prioritizing these targets, the relationships between the gene targets and the potential drugs are validated and scored using Autodock. We can then identify which drugs have the greatest potential of being repurposed to treat CRC. It is our hope that this method will be able to aid in finding new treatments for diseases without the cost and risk of developing new drugs.